WASHINGTON — In the past year alone, President Trump has bellyached about drug makers charging “rip-off” prices, numerous Democrats have accused the pharmaceutical industry of pure greed, and polls have shown that voters believe lowering the cost of prescription medicines should be among government’s top priorities.

But if Republicans prevail in just two nailbiter races on Tuesday, the Senate’s ranks would suddenly include two former drug industry lobbyists and even a pharma CEO.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The corruption/ collusion between politicians and big pharma is some scary bullshit. Educate yourself and stay away from pills people.

  • Fails to mention all of advantages Mylan received by having Manchin ignore issues and sway at the time a Democrat-majority Senate to do the same. Maybe having people with insider knowledge of the industry is a good thing, nothing else has worked.

  • Hey another biased article from STAT! Fails to mention all of advantages Mylan received by having Manchin ignore issues and sway at the time a Democrat-majority Senate to do the same. Maybe having people with insider knowledge of the industry is a good thing, nothing else has worked.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy